文献速递肝病

随机临床试验:SYNERGY-NASH 2b 期试验设计——评估替尔泊肽治疗代谢功能障碍相关脂肪性肝炎及修改筛查策略以减少筛查失败

Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.
PubMed 文献 · Aliment Pharmacol Ther · 2024-05-20

SYNERGY-NASH 为 2b 期多中心随机双盲安慰剂对照试验,评估替尔泊肽治疗活检确诊 MASH、F2-F3 纤维化且 NAFLD 活动评分≥4 的患者。试验期间采用 FAST 评分>0.35 及 AST 入选标准从>20 U/L 提高至>23 U/L 的新标准,1583 例筛查者中 190 例随机,总筛查失败率 87%。

要点

  • 新入选标准实施后,符合方案活检的总体合格率由 27.5% 变为 28.9%,不同专科间差异较大。
  • 在 29 家前后均行符合方案活检的中心,总体合格率由 26.1% 变为 29.1%。
  • 作者认为,基于肝组织学的 at-risk MASH 试验中,采用所提出的 FAST 评分和 AST 界值的新入选标准在非专科中心最有效。

核心结论

  • 对于基于肝组织学的 at-risk MASH 试验,在本试验中实施所提出的 FAST 评分和 AST 界值入选标准,在非专科中心最为有效。

研究设计与样本

  • SYNERGY-NASH 是一项 2b 期、多中心、随机、双盲、安慰剂对照试验,纳入活检确诊 MASH、F2-F3 纤维化且 NAFLD 活动评分≥4 的患者。
  • 试验期间采用新入选标准:FAST 评分>0.35,并将 AST 入选标准从>20 U/L 提高至>23 U/L,以评估其对合格率的影响。

主要发现

  • 共筛查 1583 例参与者,651 例进入肝活检,190 例被随机,总筛查失败率为 87%。
  • 方案修订后,符合方案活检的总体合格率由 27.5% 变为 28.9%,不同研究者医学专科类型间差异较大:内分泌科由 37.5% 变为 39.3%;消化科/肝病科由 26.0% 变为 23.3%;其他专科由 21.3% 变为 29.7%。
  • 在修订前后均行符合方案活检的 29 家中心,合格率变化如下:总体由 26.1% 变为 29.1%;内分泌科由 35.0% 变为 40.9%;消化科/肝病科由 25.6% 变为 20.0%;其他专科由 16.1% 变为 27.8%。

关键数值与推荐

  • 入选标准:活检确诊 MASH、F2-F3 纤维化、NAFLD 活动评分≥4。
  • 新入选标准:FAST 评分>0.35,AST 入选标准从>20 U/L 提高至>23 U/L。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of histological inclusion criteria for clinical trials of at-risk metabolic dysfunction-associated steatohepatitis (MASH) is often associated with high screen failure rates. AIMS: To describe the design of a trial investigating tirzepatide treatment of MASH and to examine the effect of new inclusion criteria incorporating the use of the FibroScan-AST (FAST) score on the proportion of patients meeting histological criteria. METHODS: SYNERGY-NASH is a Phase 2b, multicentre, randomised, double-blinded, placebo-controlled trial in patients with biopsy-confirmed MASH, F2-F3 fibrosis and NAFLD Activity Score ≥4. New inclusion criteria (FAST score >0.35 and an increase in AST inclusion criterion from >20 to >23 U/L) were adopted during the trial, allowing us to examine its impact on the qualification rate. RESULTS: 1583 participants were screened, 651 participants proceeded to liver biopsy and 190 participants were randomised with an overall screen fail rate of 87%. Following the protocol amendment, the overall qualification rate for per-protocol biopsies was minimally changed from 27.5% to 28.9% with considerable variation among different investigator medical speciality types: endocrinology: from 37.5% to 39.3%; gastroenterology/hepatology: from 26.0% to 23.3%; other specialities: from 21.3% to 29.7%. At 29 sites that performed per-protocol biopsies before and after the amendment, qualification rates changed as follows: all: 26.1% to 29.1%; endocrinology: from 35.0% to 40.9%; gastroenterology/hepatology: 25.6% to 20.0%; other specialities: from 16.1% to 27.8%. CONCLUSIONS: For at-risk MASH trials based on liver histology, the implementation of inclusion criteria with the proposed FAST score and AST cut-offs in this trial was most effective at non-specialist sites.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Vuppalanchi R, Loomba R, Sanyal AJ, et al. Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Aliment Pharmacol Ther. 2024. PMID: 38768298. doi:10.1111/apt.18042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。